30 Myeloid- Versus Effector-Driven Circulating Immune States Define Treatment-Specific Benefit in Metastatic Clear Cell Renal Cell Carcinoma
Abstract Background Metastatic clear cell renal cell carcinoma (ccRCC) first-line treatment relies on immune checkpoint inhibitor (ICI)-based regimens, including either dual ICI or ICI plus antiangiogenic tyrosine kinase inhibitor (TKI). Despite substantial clinical progress, predictive biomarkers guiding regimen selec...